¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumor associated antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • complete antigen
    ¿ÏÀüÇ׿ø
  • conjugated antigen
    Á¢ÇÕÇ׿ø, °áÇÕÇ׿ø
  • carcinoembryonic antigen
    ¾Ï¹è¾ÆÇ׿ø
  • core antigen
    ÇÙ½ÉÇ׿ø
  • cross-reacting antigen
    ±³Â÷¹ÝÀÀÇ׿ø
  • diphasic antigen
    ÀÌ»ó(ì£ßÓ)Ç׿ø
  • early antigen
    ÃʱâÇ׿ø
  • excretory-secretory antigen
    ¹è¼³ºÐºñÇ׿ø
  • egg antigen
    Ãæ¶õÇ׿ø
  • envelope antigen
    ¿ÜÇÇÇ׿ø
  • environmental antigen
    ȯ°æÇ׿ø
  • epithelial membrane antigen
    »óÇǸ·Ç׿ø
  • fimbrial antigen
    °¡´ÂÅÐÇ׿ø
  • flagellar antigen
    Æí¸ðÇ׿ø
  • formalinized antigen
    Æ÷¸£¸»¸°Ã³¸®Ç׿ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-presenting cell
    Ç׿øÀü´Þ¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • avidin-antigen conjugate
    ¾ÆºñµòÇ׿øÁ¢ÇÕü
  • capsid antigen
    ĸ½ÃµåÇ׿ø
  • capsular antigen
    ÇǸ·Ç׿ø
  • circumsporozoite antigen
    Æ÷ÀÚ¼ÒüÇ׿ø
  • colonizing factor antigen
    Áý¶ôÇü¼ºÀÎÀÚÇ׿ø
  • common antigen
    °øÅëÇ׿ø
  • complete antigen
    ¿ÏÀüÇ׿ø
  • conjugated antigen
    °áÇÕÇ׿ø, Á¢ÇÕÇ׿ø
  • core antigen
    ÇÙ½ÉÇ׿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • EBV capsid antigen (VCA)
    EB¹ÙÀÌ·¯½º ĸ½ÃµåÇ׿ø
  • EBV membrane antigen
    EB¹ÙÀÌ·¯½º ¸·Ç׿ø
  • EBV membrane antigen (MA)
    EB¹ÙÀÌ·¯½º ¸·Ç׿ø
  • Forssman antigen
    Æ÷½º¸¸Ç׿ø
  • Fy antigen/antibody
    Fy Ç׿ø/Ç×ü
  • Gag => group specifiic antigen/core
    ±×·ì<±º>ƯÀ̼º Ç׿ø/ÄÚ¾î
  • Gag antigen in HIV infection
    HIV °¨¿°ÀÇ gag Ç׿ø
  • Gag antigen:
    gag Ç׿ø
  • H antigen
    H Ç׿ø
  • H antigen
    HÇ׿ø, Æí¸ðÇ׿ø
  • H-Y histocompatibility antigen
    H-Y Á¶Á÷ÀûÇÕ¼º Ç׿ø
  • HBc Ag => hepatitis B core antigen
    B Çü °£¿° c Ç׿ø
  • HBc antigen
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
  • HBe Ag => hepatitis B e antigen
    B Çü °£¿° e Ç׿ø
  • HBe antigen
    BÇü °£¿°¹ÙÀÌ·¯½º eÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • antigen, Rh
    RhÇ׿ø
  • antigen, Thy-1
    Thy-1Ç׿ø
  • antigen, Vi
    ViÇ׿ø
  • antigen, capsular
    Çù¸·Ç׿ø
  • antigen, carcinoembryonic
    ¾ÏžÆÇ׿ø
  • antigen, colonization factor
    Áý¶ôÇü¼ºÀÎÀÚÇ׿ø, ¼¼Æ÷±ºÇü¼ºÀÎÀÚÇ׿ø
  • antigen, complete
    ¿ÏÀüÇ׿ø
  • antigen, conjugated
    °áÇÕÇ׿ø
  • antigen, cross-reacting
    ±³Â÷¹ÝÀÀÇ׿ø
  • antigen, fetal
    žÆÇ׿ø
  • antigen, fimbrial
    ¼¶¸ðÇ׿ø
  • antigen, flagellar
    Æí¸ðÇ׿ø
  • antigen, hepatitis B core
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
  • antigen, hepatitis B surface
    BÇü °£¿°¹ÙÀÌ·¯½º Ç¥¸éÇ׿ø
  • antigen, histocompatibility
    Á¶Á÷ÀûÇÕÇ׿ø
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
MTV mammary tumor virus; metatarsus varus; mouse mammary tumor virus
NET nasoendotracheal tube; nerve excitability test; neuroectodermal tumor; neuroendocrine tumor; norepin...
TC target cell; taurocholate; temperature compensation; teratocarcinoma; tertiary cleavage; tetracyclin...
TIF tumor-inducing factor; tumor-inhibiting factor
TIL tumor-infiltrating leukocyte; tumor-infiltrating lymphocyte
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
LFA-3 Lymphocyte function associated antigen-3
LFA Lymphocyte function-associated antigen
LFA-1 anti-lymphocyte function associated antigen-1
HMW-MAA high molecular weight melanoma associated antigen
MAFA mast cell function associated antigen
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • induced tumor
    Àΰø ¾Ï
    µ¿¹°¿¡°Ô ÀΰøÀûÀÎ ¾Ï¿ø¼º ÀÚ±ØÀ» ÁÖ¾î Çü¼º½ÃŲ ¾Ï. µ¿¹°ÀÇ ÀÚ¿¬¹ß»ý ¾Ï¿¡ ´ëÀÀÇÏ´Â ¸»ÀÌ´Ù.
  • intraosseous salivary gland tumor
    °ñ³» Ÿ¾×¼± Á¾¾ç
  • jaw,nonodontogenic malignant tumor
    ºñÄ¡¾Æ¼º ¾Ç¼º Á¾¾ç
  • juxtaglomerular cell tumor
    ¹æ»ç±¸Ã¼ ¼¼Æ÷ Á¾¾ç
  • juxtaglomerular tumor
    ¹æ»ç±¸Ã¼ Á¾¾ç
  • krukenberg's tumor
    Å©·çÄ˺£¸£Å© Á¾¾ç
  • lacteal tumor
    À¯¼± Á¾¾ç
  • large tumor
    Å« Á¾¾ç
  • lingual benign giant cell tumor
    ¾ç¼º °Å´ë ¼¼Æ÷ ¼³ Á¾¾ç
  • lingual tumor
    ¼³ Á¾¾ç
  • malignant carcinoid tumor
    ¾Ç¼º Ä«¸£½Ã³ëÀ̵å Á¾¾ç
  • malignant salivary gland tumor
    ¾Ç¼º Ÿ¾×¼± Á¾¾ç
  • malignant tumor
    ¾Ç¼º Á¾¾ç
    Á¤»óÀûÀÎ Á¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû, È­ÇÐÀû, »ý¹°ÇÐÀûÀÎ ¾Ï¿ø¼º ¹°ÁúÀÇ ÀÛ¿ë ¶Ç´Â ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ­ Çü¼ºµÇ´Â Á¾¾ç ¹«Á¦ÇÑÀÇ ¼¼Æ÷ ºÐ¿­·Î ¸Å¿ì ¿Õ¼ºÇÏ°Ô Áõ½ÄÇÏ¿© ÁÖÀ§ Á¶Á÷À» ÆÄ±«, ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² È­Çй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷ ¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ ¾Ç¾×ÁúÀ» ¾ß±â½ÃÄÑ Á×À½ÀÇ À§ÇèÀ» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀÎ °ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀÎ °ÍÀ» À°Á¾À̶ó ÇÑ´Ù.
  • masculinizing tumor
    ³²¼ºÈ­ Á¾¾ç
  • melanotic neuroectodermal tumor
    Èæ»ö¼º ½Å°æ ¿Ü¹è¿± Á¾¾ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
gene rearrangement, beta-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the beta-chain of antigen receptors.
(12 Dec 1998)
gene rearrangement, delta-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the delta-chain of antigen receptors.
(12 Dec 1998)
gene rearrangement, gamma-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the gamma-chain of antigen receptors.
(12 Dec 1998)
M antigen An antigen found in the cell of Streptococcus pyogenes; associated with virulence.
See: beta-haemolytic streptococci.
(05 Mar 2000)
receptor-CD3 complex, antigen, T-cell Molecule composed of the non-covalent association of the T-cell antigen receptor (receptors, antigen, T-cell) with the CD3 complex (antigens, CD3). This association is required for the surface expression and function of both components. The molecule consists of up to seven chains: either the alpha/beta or gamma/delta chains of the T-cell receptor, and four or five chains in the CD3 complex.
(12 Dec 1998)
receptors, antigen Molecules on the surface of b- and T-lymphocytes that recognise and combine with specific antigens.
(12 Dec 1998)
receptors, antigen, B-cell Immunoglobulin molecules on the surface of B-lymphocytes that recognise and bind antigen.
(12 Dec 1998)
receptors, antigen, T-cell Molecules on the surface of T-lymphocytes that recognise and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (antigens, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (receptors, antigen, T-cell, alpha-beta) or gamma-delta (receptors, antigen, T-cell, gamma-delta) chains.
(12 Dec 1998)
receptors, antigen, T-cell, alpha-beta T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognise antigens only when presented in association with major histocompatibility (MHC) molecules.
(12 Dec 1998)
receptors, antigen, T-cell, gamma-delta T-cell receptors composed of CD3-associated gamma and delta polypeptide chains and expressed primarily in CD4-/CD8- T-cells. The receptors appear to be preferentially located in epithelial sites and probably play a role in the recognition of bacterial antigens. The T-cell receptor gamma/delta chains are separate and not related to the gamma and delta chains which are subunits of CD3 (see antigens, CD3).
(12 Dec 1998)
receptors, very late antigen Members of the integrin family appearing late after T-cell activation. They are a family of proteins initially identified at the surface of stimulated T-cells, but now identified on a variety of cell types. At least six vla antigens have been identified as heterodimeric adhesion receptors consisting of a single common beta-subunit and different alpha-subunits.
(12 Dec 1998)
Gerbich antigen glycophorin C
Vi antigen Virulence antigen, an external capsular antigen of enterobacteria formerly thought to be related to increased virulence.
(05 Mar 2000)
partial antigen <immunology, molecular biology> Could be considered an isolated epitope: although a hapten (by definition) has an antibody directed against it, the hapten alone will not induce an immune response if injected into an animal, it must be conjugated to a carrier (usually a protein).
The hapten constitutes a single antigenic determinant, perhaps the best known example is dinitro phenol (DNP) that can be conjugated to BSA and against which antiDNP antibodies are produced (antibodies to the BSA can be adsorbed out).
Because the hapten is monovalent, immune complex formation will be blocked if the soluble hapten is present as well as the hapten carrier conjugate (assuming there is more than one hapten per carrier then an immune precipitate can be formed).
Competitive inhibition by the soluble small molecule is sometimes referred to as haptenic inhibition and this term has carried over into lectin mediated haemagglutination where monosaccharides are added to try to block haemagglutination: the blocking sugar defines the specificity of the lectin.
(18 Nov 1997)
viral antigen Those antigens specified by the viral genome (often coat proteins) that can be detected by a specific immunological response. Often of diagnostic importance.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á